微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 30.7% | -8.78% | -2.37% | 114/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 31.45% | -8.91% | 14.03% | 114/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 27.58% | -24.78% | -16.45% | 119/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 33.01% | -0.87% | -1.93% | 116/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 33.66% | 7.59% | -2.51% | 111/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 34.53% | 3.58% | -5.83% | 112/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 36.67% | 2.17% | 10.11% | 102/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 33.3% | 2.69% | 6.44% | 111/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 31.29% | 6.73% | -6.14% | 117/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 33.33% | 18.45% | -7.12% | 114/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 35.89% | 16.96% | 10.67% | 109/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 32.43% | 7.36% | 10.63% | 117/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 29.31% | -2.81% | 4.16% | 117/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 28.14% | -4.36% | -8.29% | 123/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 30.69% | 7.34% | 1.59% | 110/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 30.21% | -13.56% | 0.15% | 126/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 30.16% | -13.04% | 2.51% | 115/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 29.42% | -12.69% | 2.93% | 125/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 28.59% | -21.22% | -18.19% | 109/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 34.94% | 17.49% | 0.75% | 116/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 34.68% | 13.62% | 2.92% | 101/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 33.7% | 20.22% | -7.13% | 110/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 36.29% | 57.17% | 22% | 88/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 29.74% | 1.62% | -2.57% | 118/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 30.53% | 8.38% | 8.9% | 95/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 28.03% | 3.21% | 21.42% | 105/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 23.09% | -9.41% | -21.12% | 97/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 29.27% | -20.02% | 3.92% | 118/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 28.17% | -25.7% | 3.71% | 91/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 27.16% | -30.56% | 6.57% | 99/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 25.49% | -34.64% | -30.36% | 94/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 36.6% | -5.47% | -3.46% | 86/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 37.91% | 2% | -3.08% | 65/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 39.11% | -5.14% | 0.31% | 65/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 38.99% | 2% | 0.71% | 51/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 38.71% | -2.63% | -6.1% | 71/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 41.23% | -0.32% | 3.7% | 49/159 | 45.89% | 贝达药业 | 95.89% | 行业排名> |
| 2015-12-31 | 39.76% | 2% | -3.88% | 58/159 | 45.97% | 微芯生物 | 97.46% | 行业排名> |
| 2015-06-30 | 41.36% | 2% | 2% | 43/159 | 45% | 贝达药业 | 97.01% | 行业排名> |